Therapy Areas: Central Nervous System
South Rampart Pharma reports new study findings showing SRP-001 delivers central, non-toxic pain relief
29 July 2025 - South Rampart Pharma Inc, a US-based clinical-stage biopharmaceutical company focused on innovative non-opioid pain therapies, announced on Monday the publication of new research in the...
NFL Biosciences and McLean Hospital collaborate to advance NFL-101 mechanism research
28 July 2025 - Biopharmaceutical company NFL Biosciences (Euronext Growth Paris: ALFNL) announced on Monday that it has entered into a scientific collaboration with McLean Hospital, part of the Mass G...
Neuraxpharm launches Neuraxpharm Australia
22 July 2025 - Neuraxpharm Group, a Spain-based specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announced on Monday the launch of a new affiliate, ...
Zhimeng Biopharma's CB03-154 ALS Phase 2/3 study receives Chinese clinical trial approval
10 July 2025 - Shanghai Zhimeng Biopharma Inc, a Chinese clinical-stage biopharmaceutical company involved in drug development for liver and central nervous system (CNS) diseases, announced on Wednesd...
Mycovia Pharmaceuticals reports first participant enrolled in Phase 2 cryptococcal meningitis study
5 June 2025 - US pharmaceutical company Mycovia Pharmaceuticals Inc announced on Wednesday that the first participant has been enrolled in an investigator-initiated clinical trial evaluating otesecona...
Estrella Immunopharma initiates second cohort in EB103 trial for advanced B-cell lymphomas
29 May 2025 - Clinical stage biopharmaceutical company Estrella Immunopharma Inc (NASDAQ:ESLA) reported on Thursday that the first patient has been dosed in the second cohort of its Phase I/II STARLIG...